BL-B01D1 binds EGFR/HER3 on tumor cells, is internalized, and releases the topoisomerase I inhibitor brengitecan that causes DNA damage and apoptosis. Topoisomerase I is the intracellular enzymatic target of the payload, not the antigen recognized by the ADC.